CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, Guo T, Gu Y, Wu J, Gao J, Zhao X, He Z.
J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB.
Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, Dubrot J, Doench JG, Regev A, Vander Heiden MG, Maus MV, Manguso RT, Birnbaum ME, Hemann MT.
Nat Commun. 2023 Dec 5;14(1):8048. doi: 10.1038/s41467-023-43790-2.
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
Oh BLZ, Vinanica N, Wong DMH, Campana D.
Haematologica. 2024 Jun 1;109(6):1677-1688. doi: 10.3324/haematol.2023.283848.
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
Bexte T, Botezatu L, Miskey C, Gierschek F, Moter A, Wendel P, Reindl LM, Campe J, Villena-Ossa JF, Gebel V, Stein K, Cathomen T, Cremer A, Wels WS, Hudecek M, Ivics Z, Ullrich E.
Mol Ther. 2024 Jul 3;32(7):2357-2372. doi: 10.1016/j.ymthe.2024.05.022. Epub 2024 May 14.
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A.
Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.
Weinberg OK, Bueso-Ramos CE, Kanagal-Shamanna R.
Am J Clin Pathol. 2025 Jul 11;164(1):26-35. doi: 10.1093/ajcp/aqaf015.
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M.
Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.
TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M, Dìaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S, Duval M.
Oncotarget. 2015 Oct 6;6(30):29440-55. doi: 10.18632/oncotarget.4984.
